BAUSCH HEALTH COS INC (BHC) Stock Fundamental Analysis
NYSE:BHC • CA0717341071
5.93 USD
-0.11 (-1.82%)
At close: Feb 27, 2026
5.93 USD
0 (0%)
After Hours: 2/27/2026, 8:04:00 PM
We assign a fundamental rating of 4 out of 10 to BHC. BHC was compared to 192 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of BHC while its profitability can be described as average. BHC is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year BHC was profitable.
- BHC had a positive operating cash flow in the past year.
- BHC had negative earnings in 4 of the past 5 years.
- Of the past 5 years BHC 4 years had a positive operating cash flow.
1.2 Ratios
- BHC has a better Return On Assets (0.60%) than 79.27% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 7.78%, BHC belongs to the top of the industry, outperforming 87.05% of the companies in the same industry.
- BHC had an Average Return On Invested Capital over the past 3 years of 6.89%. This is significantly below the industry average of 12.96%.
- The 3 year average ROIC (6.89%) for BHC is below the current ROIC(7.78%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROIC | 7.78% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
1.3 Margins
- The Profit Margin of BHC (1.53%) is better than 79.27% of its industry peers.
- The Operating Margin of BHC (21.28%) is better than 88.60% of its industry peers.
- In the last couple of years the Operating Margin of BHC has grown nicely.
- With a decent Gross Margin value of 70.65%, BHC is doing good in the industry, outperforming 78.76% of the companies in the same industry.
- In the last couple of years the Gross Margin of BHC has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% |
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
2. Health
2.1 Basic Checks
- BHC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for BHC has been increased compared to 1 year ago.
- Compared to 5 years ago, BHC has more shares outstanding
- The debt/assets ratio for BHC has been reduced compared to a year ago.
2.2 Solvency
- BHC has an Altman-Z score of 0.29. This is a bad value and indicates that BHC is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 0.29, BHC is in line with its industry, outperforming 51.81% of the companies in the same industry.
- BHC has a debt to FCF ratio of 21.00. This is a negative value and a sign of low solvency as BHC would need 21.00 years to pay back of all of its debts.
- The Debt to FCF ratio of BHC (21.00) is better than 77.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Altman-Z | 0.29 |
ROIC/WACC1.18
WACC6.58%
2.3 Liquidity
- A Current Ratio of 1.47 indicates that BHC should not have too much problems paying its short term obligations.
- The Current ratio of BHC (1.47) is worse than 70.98% of its industry peers.
- BHC has a Quick Ratio of 1.08. This is a normal value and indicates that BHC is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.08, BHC is not doing good in the industry: 76.17% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 |
3. Growth
3.1 Past
- BHC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
- Measured over the past years, BHC shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.13% on average per year.
- Looking at the last year, BHC shows a small growth in Revenue. The Revenue has grown by 6.66% in the last year.
- BHC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.04% yearly.
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
3.2 Future
- BHC is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.02% yearly.
- BHC is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.38% yearly.
EPS Next Y13.77%
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
EPS Next 5Y-2.02%
Revenue Next Year4.23%
Revenue Next 2Y2%
Revenue Next 3Y-2.31%
Revenue Next 5Y-1.38%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 1.57, which indicates a rather cheap valuation of BHC.
- Based on the Price/Earnings ratio, BHC is valued cheaply inside the industry as 99.48% of the companies are valued more expensively.
- When comparing the Price/Earnings ratio of BHC to the average of the S&P500 Index (27.10), we can say BHC is valued rather cheaply.
- Based on the Price/Forward Earnings ratio of 1.38, the valuation of BHC can be described as very cheap.
- Based on the Price/Forward Earnings ratio, BHC is valued cheaply inside the industry as 98.96% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 28.06. BHC is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.57 | ||
| Fwd PE | 1.38 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BHC is valued cheaply inside the industry as 94.30% of the companies are valued more expensively.
- 99.48% of the companies in the same industry are more expensive than BHC, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.21 | ||
| EV/EBITDA | 6.41 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of BHC may justify a higher PE ratio.
- BHC's earnings are expected to decrease with -7.27% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
5. Dividend
5.1 Amount
- BHC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.93
-0.11 (-1.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2026-02-20/amc
Earnings (Next)04-28 2026-04-28
Inst Owners45.78%
Inst Owner Change-1.83%
Ins Owners10.79%
Ins Owner Change11.68%
Market Cap2.20B
Revenue(TTM)10.27B
Net Income(TTM)157.00M
Analysts48.89
Price Target7.43 (25.3%)
Short Float %1.66%
Short Ratio2.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.64%
Min EPS beat(2)-13.87%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-10.87%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)3
Avg EPS beat(8)-7.33%
EPS beat(12)6
Avg EPS beat(12)-4.52%
EPS beat(16)7
Avg EPS beat(16)-7.67%
Revenue beat(2)2
Avg Revenue beat(2)1.43%
Min Revenue beat(2)0.64%
Max Revenue beat(2)2.23%
Revenue beat(4)3
Avg Revenue beat(4)0.41%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.23%
Revenue beat(8)6
Avg Revenue beat(8)0.66%
Revenue beat(12)9
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)0.16%
PT rev (1m)1.04%
PT rev (3m)2.3%
EPS NQ rev (1m)16.33%
EPS NQ rev (3m)16.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0.65%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.57 | ||
| Fwd PE | 1.38 | ||
| P/S | 0.21 | ||
| P/FCF | 2.21 | ||
| P/OCF | 1.57 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.41 |
EPS(TTM)3.77
EY63.58%
EPS(NY)4.29
Fwd EY72.33%
FCF(TTM)2.68
FCFY45.15%
OCF(TTM)3.78
OCFY63.66%
SpS27.68
BVpS-1.49
TBVpS-44.41
PEG (NY)0.11
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROCE | 9.85% | ||
| ROIC | 7.78% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 34.78% | ||
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% | ||
| FCFM | 9.67% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
ROICexc(3y)7.29%
ROICexc(5y)6.47%
ROICexgc(3y)46.04%
ROICexgc(5y)39.55%
ROCE(3y)8.72%
ROCE(5y)7.82%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y7.05%
ROICexc growth 3Y16.83%
ROICexc growth 5Y15.41%
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Debt/EBITDA | 6.08 | ||
| Cap/Depr | 33.69% | ||
| Cap/Sales | 3.96% | ||
| Interest Coverage | 1.42 | ||
| Cash Conversion | 41.26% | ||
| Profit Quality | 632.48% | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | 0.29 |
F-Score6
WACC6.58%
ROIC/WACC1.18
Cap/Depr(3y)27.35%
Cap/Depr(5y)23.9%
Cap/Sales(3y)3.53%
Cap/Sales(5y)3.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
EPS Next Y13.77%
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
EPS Next 5Y-2.02%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
Revenue Next Year4.23%
Revenue Next 2Y2%
Revenue Next 3Y-2.31%
Revenue Next 5Y-1.38%
EBIT growth 1Y17.85%
EBIT growth 3Y16.27%
EBIT growth 5Y10.72%
EBIT Next Year33.3%
EBIT Next 3Y-2.01%
EBIT Next 5Y1.07%
FCF growth 1Y-21%
FCF growth 3YN/A
FCF growth 5Y4.37%
OCF growth 1Y-12.34%
OCF growth 3YN/A
OCF growth 5Y4.73%
BAUSCH HEALTH COS INC / BHC FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.
Can you provide the valuation status for BAUSCH HEALTH COS INC?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC). This can be considered as Undervalued.
Can you provide the profitability details for BAUSCH HEALTH COS INC?
BAUSCH HEALTH COS INC (BHC) has a profitability rating of 6 / 10.
Can you provide the financial health for BHC stock?
The financial health rating of BAUSCH HEALTH COS INC (BHC) is 3 / 10.